Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
3.62
Nov 13 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Aftermarket Close
3.62
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
249.95M
Enterprise Value
118.59M
Income
-48.51M
Sales
116.23M
Book/sh
4.45
Cash/sh
2.15
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
501
IPO
Nov 17, 1986
P/E
-
Forward P/E
-
PEG
-
P/S
2.15
P/B
0.81
P/C
1.69
P/FCF
-
EV/EBITDA
-
EV/Sales
1.02
Quick Ratio
7.36
Current Ratio
8.58
Debt/Eq
0.05
LT Debt/Eq
0.05
Option/Short
Yes / Yes
EPS (ttm)
-0.69
EPS next Y
-0.61
EPS next Q
-0.17
EPS this Y
36.70%
EPS next Y
-3.36%
EPS next 5Y
20.63%
EPS past 3/5Y
-58.18% -33.45%
Sales past 3/5Y
-33.29% -7.70%
EPS Y/Y TTM
14.93%
Sales Y/Y TTM
-7.53%
EPS Q/Q
-1.06%
Sales Q/Q
14.11%
Insider Own
6.61%
Insider Trans
1.67%
Inst Own
86.49%
Inst Trans
-2.23%
ROA
-12.56%
ROE
-14.50%
ROIC
-15.07%
Gross Margin
39.54%
Oper. Margin
-59.70%
Profit Margin
-41.73%
SMA20
-3.26%
SMA50
-2.76%
SMA200
1.84%
Trades
Shs Outstand
69.04M
Shs Float
64.48M
52W High
4.58 -20.96%
52W Low
2.08 74.04%
Volatility
6.71% 6.39%
ATR (14)
0.23
RSI (14)
47.63
Beta
1.06
Rel Volume
0.71
Avg Volume
576.41K
Volume
409,010
Perf Week
5.23%
Perf Month
-4.99%
Perf Quarter
-4.99%
Perf Half Y
20.67%
Perf YTD
49.59%
Perf Year
58.77%
Perf 3Y
-44.65%
Perf 5Y
-63.62%
Perf 10Y
-56.44%
Prev Close
3.62
Price
3.62
Change %
0.00%
Consensus
Buy
Avg. Price Target
$5.50
Implied Upside
+51.9%
Analysts11incl. previous ratings
Rating Distribution5 Buy · 6 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jan 03, 2023Resumed
EVR logoEEvercore ISI
In-line$5+38.1%
Sep 22, 2021Downgrade
RJF logoRRaymond James
Outperform → Mkt Perform
Aug 21, 2020Initiated
EVR logoEEvercore ISI
Outperform$22+507.7%
Aug 10, 2020Initiated
JPM logoJJP Morgan
Neutral$18+397.2%
Aug 10, 2020Initiated
C logoCCitigroup
Buy$18+397.2%
Aug 07, 2020Upgrade
RJF logoRRaymond James
Mkt Perform → Outperform$16+342.0%
Jun 25, 2020Initiated
LLake Street
Buy$19+424.9%
Apr 21, 2020Resumed
SStephens
Equal-Weight$14+286.7%
Oct 23, 2018Resumed
RJF logoRRaymond James
Mkt Perform
Jul 16, 2018Downgrade
SStephens
Overweight → Equal-Weight
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boyd Steven KyleDirectorMay 13 '26Buy3.0225,00075,50088,462May 14 08:55 PM
Boyd Steven KyleDirectorMay 14 '26Buy2.9925,00074,750113,462May 14 08:55 PM
Boyd Steven KyleDirectorMay 12 '26Buy2.9825,00074,50063,462May 14 08:55 PM
McGrath Kenneth JChief Financial OfficerMar 20 '26Buy2.9332,30094,600589,562Mar 23 07:23 PM
EGLINTON MANNER CARRIEPresident & CEOMar 20 '26Buy2.9332,30094,5972,190,874Mar 23 07:23 PM
McGrath Kenneth JChief Financial OfficerMar 13 '26Buy3.0022,02166,030557,262Mar 16 08:01 PM
EGLINTON MANNER CARRIEPresident & CEOMar 13 '26Buy3.0022,02266,0332,158,574Mar 16 08:01 PM
Mara AspinallBoardDec 04 '25Proposed Sale2.5189,716225,000Dec 04 01:45 PM
Gagliano Nancy JDirectorNov 28 '25Buy2.372,1004,982160,254Dec 02 04:16 PM
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.
PresidentMs. Carrie Eglinton Manner
Chief Financial OfficerMr. Kenneth J. McGrath
Senior VPMs. Michele Anthony
Diagnostics R&D & Chief TechnologistMs. Karen Davies
Sample Management Solutions R&D & Chief ScientistMr. Rafal Iwasiow Ph.D.